Forward Science Licenses Cold Sore Drug Sitavig from EPI Health

Posted: August 8, 2018
Edited by Dentaltown staff

HOUSTON—Forward Science and EPI Health have entered into an exclusive agreement licensing Sitavig to Forward Science in the dental market. Sitavig, which is FDA approved, is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults. 

Cold sores, also called fever blisters, are common viral infections that are caused most often by the herpes simplex virus (HSV-1). Cold sores are contagious even if you do not see the sores. Antiviral medications can help cold sores heal more quickly and may reduce how often they return, however there is no cure for HSV infection. The current method of treating cold sores is to alleviate the symptoms, reduce the duration of the outbreak and reduce the number of outbreaks.

“We are excited to continue to bring advanced products to the dental market that frequently get overlooked”, said Forward Science CEO Robert J. Whitman. “As physicians of the mouth, dentistry has an opportunity to change lives affected from the negative stigma of cold sores, and Sitavig is the best product to do that with.” 

The most common treatment method currently used for cold sores is prolonged systemic dosing of acyclovir.

“Sitavig's active drug is also acyclovir, but its proprietary delivery system produces several distinct advantages over the current standard of treatment," said Forward Science Chief Technology Officer Brian Pikkula.

Sitavig is a single dose which increases compliance and ease of use for the patient. The local targeting of Sitavig to the oral mucosa provides a marked increase in salivary concentration of the active drug where it is needed, while at the same time giving orders of magnitude lower plasma concentration of acyclovir resulting in reduced side effects.  Because of the locally targeted therapy, a third of patients in the clinical trial did not progress to break out and those with recurrent cold sores experienced a significant delay before their next episode. 

“Sitavig has predominately been marketed to the dermatology market with much success," said Chuck Jenkins, EPI vice president of commercial operations and strategy, “Forward Science has shown success in launching new products to the dental market, and we are excited to partner with them in efforts to get Sitavig to more patients.”
For more information, visit


Townie Perks

Townie® Poll

Do you plan to retire by 2028?

Site Help

Sally Gross, Member Services
Phone: +1-480-445-9710

Follow Dentaltown

Mobile App



9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 · Phone: +1-480-598-0001 · Fax: +1-480-598-3450
©1999-2019 Dentaltown, L.L.C., a division of Farran Media, L.L.C. · All Rights Reserved